Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication and its Correlation With the Segment of Arterial Obstruction

Abstract

The metabolic syndrome (MetS) is associated with increased cardiovascular morbidity and mortality. Intermittent claudication reflects the presence of peripheral arterial disease (PAD). The aim of this study is to determine the prevalence of the MetS in claudicants and its correlation with age, gender, localization of arterial obstruction, and symptomatic coronary disease. Patients (n = 170) with intermittent claudication were studied. The mean age was 65 years (33-89). Metabolic syndrome was diagnosed in 98 patients (57.6%). The mean age of patients with MetS was 63.5 years compared with 67.0 years for patients without MetS (P = .027). Considering patients aged ≥65 years, MetS was present in 46 (48.9%) individuals and in 52 (68.4%) patients younger than 65 years (P = .011). Metabolic syndrome must be actively searched for in claudicant patients.

Keywords

claudication atherosclerosis peripheral arterial disease insulin resistance metabolic syndrome

Get full access to this article

View all access options for this article.

References

Ford ES , Giles WH A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26(3):575-581.

Haffner S. , Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation . 2003;108(13):1541-1545.

Girman CJ , Rhodes T. , Mercuri M. , et al, and 4S Group and the AFCAPS/TexCAPS Research Group The metabolic syndrome risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93(2):136-141.

Baum MK , Rafie C. , Lai S. , et al. Coronary heart disease (CHD) risk factors and metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis. 2006;2(3):173-179.

Zonana-Nacach A. , Santana-Sahagún E. , Jiménez-Balderas FJ , Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008;14(2):74-77.

Boke O. , Aker S. , Sarisoy G. , Saricicek EB , Sahin AR Prevalence of metabolic syndrome among inpatients with schizophrenia . Int J Psychiatry Med. 2008;38(1):103-112.

Olijhoeka JK , van der Graaf Y. , Banga JD , Algra A. , Rabelink TJ , Visseren FLJ; the SMART Study Group. The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J . 2004;25(4):342-348.

Gorter PM , Olijhoek JK , van der Graaf Y. , Algra A. , Rabelink TJ , Visseren FLJ ; SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173(2):363-369.

Gang H. , Qiao Q. , Tuomilehto J. , Balkau B. , Borch-Johnsen K. , Pyorala K. ; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066-1076.

10.

Lakka HM , Laaksonen DE , Lakka TA , et al. The metabolic Syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-2716.

11.

Brower BG , Visseren FL , Stolk RP , van der Graaf Y. ; SMART Study Group. Abdominal fat and risk of coronary heart disease in patients with peripheral arterial disease. Obesity. 2007;15(6): 1623-1630.

12.

Rutherford RB , Baker JD , Ernst C. , et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version . J Vasc Surg. 1997;26(3):517-538.

13.

Wolosker N. , Rosoky RA , Nakano L. , Basyches M. , Puech-Leão P. Predictive value of the ankle-brachial index in the evaluation of intermittent claudication . Rev Hosp Clin Fac Med Sao Paulo. 2000;55(2):61-64.

14.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-3421.

15.

Grundy SM , Brewer HB Jr , Cleeman JI , Smith SC Jr , Lenfant C. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109(3):433-438.

16.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486-2497.

17.

Grundy SM , Cleeman JI , Merz CN , et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation . 2004;110: 227-239.

18.

Pi-Sunyer. The metabolic syndrome: how to approach differing definitions. Am J Clin North Am. 2007;91(6):1025-1040.

19.

Criqui MH , Langer RD , Fronek A. , et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-386.

20.

Brass EP , Hiatt WR Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vasc Med. 2006;11(3):141-145.

21.

Vogt MT , Wolfson SK , Kuller LH Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol. 1992; 45(5):529-542.

22.

Katzel LI , Sorkin JD , Powell CC , Gardner AW Comorbidities and exercise capacity in older patients with intermittent claudication . Vasc Med. 2001;6(3):157-162.

23.

Lorenzo C. , Williams K. , Hunt KJ , Haffner SM Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care . 2006;29(3):625-630.

24.

Sundstrom J. , Riserus U. , Byberg L. , Zethelius B. , Lithell H. , Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006 ;332(7546):878-882.

25.

Golledge J. , Leicht A. , Crowther RG , Clancy P. , Spinks WL , Quigley F. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg. 2007;45(1):40-46.

26.

Gardner AW , Montgomery PS The effect of metabolic syndrome components on exercise performance in patients with intermittent claudication. J Vasc Surg. 2008;47(6):1251-1258.

27.

Ford ES Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care . 2005;28(11):2745-2749.

28.

Ford ES , Giles WH A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26(3):575-581.

29.

Ford ES , Giles WH , Dietz WH Prevalence of the metabolic syndrome among US adults. Findings from the third National Health and Nutrition Examinations Survey. JAMA. 2002;287(3): 356-359.

30.

Salaroli LB , Barbosa GC , Mill JG , Molina MC. Prevalence of metabolic syndrome in population-based study, Vitória, ES-Brazil . Arq Bras Endocrinol Metabol. 2007;51(7): 1143-1152.

31.

Nakazone MA , Pinheiro A. , Braile MC , Pinhal MA , de Sousa GF Prevalence of metabolic syndrome using NCEP-ATP III and IDF definitions in Brazilian individuals. Rev Assoc Med Bras. 2007; 53(5):407-413.

32.

Maksimovic M. , Vlajinac H. , Radak D. , Marinkovic J. , Jorga J. Relationship between peripheral arterial disease and metabolic syndrome. Angiology. 2009;60(5):546-553.

33.

Ambrosetti M. , Salerno M. , Laporta A. , Pedretti RFE. Metabolic Syndrome in patients with intermittent claudication referred to vascular rehabilitation . Int Angiol . 2006;25(1):14-17.

34.

Wassink AMJ , van der Graaf Y. , Olijhoek JK , Visseren FLJ for the SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2008;29(2): 213-223.

35.

van Kuijk JP , Flu WJ , Chonchol M. , Bax JJ , Verhagen HJ , Poldermans D. Metabolic syndrome is an independent predictor of cardiovascular events in high-risk patients with occlusive and aneurysmatic peripheral arterial disease. Atherosclerosis. 2009 Dec 22. [Epub ahead of print].

36.

Qadan LR , Ahmed AA , Safar HA , Al-Bader MA , Ali AA Prevalence of metabolic syndrome in patients with clinically advanced peripheral vascular disease. Angiology. 2008 ;59(2): 198-202.

37.

Athyros VG , Ganotakis ES , Tziomalos K. , Papageorgiou AA , Anagnostis P. , Griva T. , et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin. 2010 Jan 18. [Epub ahead of print].

38.

Wolosker N. , Nakano L. , Rosoky RA , Puech-Leão P. Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. Arch Intern Med. 2003;163(19s):2296-2300.